Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
induced pluripotent stem cell-derived natural killer cells with autocrine feeder signaling
- Development stage
- Preclinical
- Lead developer
- Yi-Chen Sun
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Induced pluripotent stem cell-derived natural killer cells with autocrine feeder signaling are an experimental adoptive cellular immunotherapy designed to overcome the expansion and persistence limitations of conventional NK cell products. These cells are generated by differentiating human induced pluripotent stem cells (iPSCs) into hematopoietic progenitors and subsequently into mature NK cells. To eliminate the need for exogenous feeder cells (such as irradiated K562 cells) and exogenous cytokines, the cells are genetically engineered via viral transduction to express a self-feeder system consisting of CD86, 4-1BB ligand (4-1BBL), and a bispecific single-chain variable fragment (scFv) targeting interleukin-21 (IL-21) signaling. This autocrine loop provides continuous costimulatory and cytokine signals, promoting robust cell proliferation, prolonged viability, and enhanced cytotoxic activity against malignant cells even after repeated challenges.
- Other names
- self-supporting iNK cellsiPSC-derived NK cells with autocrine feeder signalingengineered iNK cells with autocrine feeder signaling
Beyond the preview
Go deeper on induced pluripotent stem cell-derived natural killer cells with autocrine feeder signaling.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on induced pluripotent stem cell-derived natural killer cells with autocrine feeder signaling.